Long-Term Efficacy, Tolerability, and Renal Safety of Atazanavir/Ritonavir-based Antiretroviral Therapy in a Cohort of Treatment-Naïve Patients with HIV-1 Infection: the REMAIN Stu...

por Teófilo, Eugénio, Rocha-Pereira, Nuno, Kuhlmann, Birger, Antela, Antonio, Knechten, Heribert, Santos, Jesús, Jiménez-Expósito, Maria Jesús
Publicado 2016

Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+)

por Leroy, Vincent, Angus, Peter, Bronowicki, Jean‐Pierre, Dore, Gregory J., Hezode, Christophe, Pianko, Stephen, Pol, Stanislas, Stuart, Katherine, Tse, Edmund, McPhee, Fiona, Bhore, Rafia, Jimenez‐Exposito, Maria Jesus, Thompson, Alexander J.
Publicado 2016

Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world...

por Welzel, Tania M, Petersen, Jörg, Herzer, Kerstin, Ferenci, Peter, Gschwantler, Michael, Wedemeyer, Heiner, Berg, Thomas, Spengler, Ulrich, Weiland, Ola, van der Valk, Marc, Rockstroh, Jürgen, Peck-Radosavljevic, Markus, Zhao, Yue, Jimenez-Exposito, Maria Jesus, Zeuzem, Stefan
Publicado 2016